How Predictive Analytics Shapes Pharma's Future

In the recent past, drug development for widespread diseases could take decades. HIV treatments developed in the 1980s and 1990s took over a decade to reach the market, resulting in millions of deaths before the introduction of Highly Active Antiretroviral Therapy (HAART) in 1996.

In 2020, vaccines against COVID-19 were approved globally in under a year and helped mitigate a global health crisis much faster. This is largely thanks to predictive analytics in pharma, a cluster of data mining techniques that analyze historical data and make accurate predictions about future outcomes.

In this article, we look into the current state and future potential of predictive analytics in drug development, using real-world examples.

Overview of predictive analytics technology in pharma

The market of pharma manufacturing analytics is already significant, but it will likely grow into an even bigger powerhouse. To be precise, the global predictive analytics market is estimated at 14.58 billion dollars in 2023 and is expected to grow at a CAGR of 24.0% through 2030. The market is accelerated by the demand for technologies that improve patient outcomes and reduce costs, as well as by advancements in AI and machine learning (Source ).

The growing pool of big data also creates opportunities for advanced healthcare solutions, with more hospitals adopting certified EHRs. The pharma predictive analytics innovations were accelerated by the need to respond to the COVID-19 pandemic.

The potential of predictive analytics in the pharmaceutical industry is vast. A study by McKinsey estimates that top pharmaceutical companies using predictive analytics for real-world evidence (RWE) generation can unlock more than $300 million annually over the next 3-5 years.

These savings primarily come from optimizing clinical trials, reducing R&D costs, and accelerating time to market for new drugs​ (Source ). Using predictive analytics in pharma also allows companies to proactively manage their supply chains by forecasting demand spikes and identifying potential disruptions.

How predictive analytics is revolutionizing the pharmaceutical industry

Pharmaceutical manufacturing is associated with enormous costs. This includes costs related to drug discovery, preclinical research, the clinical trial phases (I, II, III), and post-market studies, all essential and equally important components of the drug's journey to market. A study by the Tufts Center for the Study of Drug Development estimates the total cost at around $2.6 billion when accounting for both out-of-pocket expenses and the time costs associated with bringing a new drug to market​ (Source ). And mind it, this is just for a single drug.

Moreover, the development cycle can take up to a whopping 15 years, including a complex bureaucratic regulatory review.

Not only is the journey long and expensive, but the success is also not guaranteed. In fact, the success rate for drugs moving from preclinical testing to regulatory approval is low. Only about 12% of drugs that enter clinical trials eventually gain FDA approval.

The success rate can vary by therapeutic area; for example, oncology drugs tend to have lower approval rates compared to other fields, for example, cardiovascular drugs (Source). Predictive analytics (along with aid in pharma R&D) accelerate new drug development and optimize clinical trials, thereby reducing R&D costs and accelerating time to market. While predictive analytics in drug development is not a magical pill that can solve these issues in an instant, it has already proved to be effective in many ways. Here is how it can help:

1. Forecasting drug efficacy and side effects

Predictive analytics in pharmaceutical research allows pharmaceutical companies to anticipate how a drug will perform in specific patient populations before it enters large-scale clinical trials.

For instance, companies are using machine learning algorithms to predict adverse drug reactions by examining previous clinical trial data and patient electronic health records (EHRs).

The effects of simulated interventions, like thrombectomy in patients with ischemic stroke, can also be simulated in predictive models. This is great for instances where randomized control trials are too expensive.

2. Accelerating new drug development with big data

Pharma predictive analytics accelerates new drug development with big data. The main issue with drug development is the gregariously high costs. In particular, predictive analytics reduces reliance on traditional randomized control trials (RCTs) by using historical data and creating virtual patient cohorts.

Some top pharma companies have reported savings of up to $100 million annually in R&D costs by optimizing trial design and using synthetic control arms​ (Source ). A synthetic control arm uses existing data from past patients or medical records to replace a control group in a clinical trial. Instead of an actual control group, you get an imagined one from clinical data.

Predictive analytics can also enhance and even potentially replace animal studies used in the early stages of drug development, as it is now the consensus that they do not accurately reflect the outcomes of treatments and drugs for humans. However, a realistic total replacement is possible only when AI systems develop toward a more accurate representation of human biology.

3. Predicting clinical trial outcomes

Predictive models are highly effective in forecasting clinical trial outcomes. For example, time-series modeling and machine learning predict patient dropout rates and adverse events in clinical trials. In particular, they can predict drug-related side effects and hypoglycemia in diabetic patients.

Pharma data analytics can also optimize costs spent on clinical trials by making the process more efficient: selecting the right candidates and predicting their responses to treatment. For instance, predictive analytics in pharma uses historical data to calculate the right sample sizes for trials (Source ).

4. Optimizing manufacturing processes and supply chain management

Supply chain optimization is one of the most impactful applications of predictive analytics in pharma. During the COVID-19 pandemic, predictive analytics played a crucial role in forecasting demand surges for vaccines and treatments.

Pharmaceutical companies used agent-based models (ABM) and machine learning algorithms to simulate global vaccine demand and anticipate shortages. For example, computational models developed for COVID-19 vaccination strategies took into account over 90% of the global population and 95% of global cases to optimize distribution efforts. Beyond COVID, a similar model could be used to optimize the demand for any high-demand drug.

Benefits of predictive analytics for pharma

Given everything we discussed, here is the comprehensive list of potential benefits of pharma predictive analytics:

• Shorter drug development time
• Reduced risks and side effects of drugs
• Optimized supply chain and better inventory
• Cost savings across the entire journey of drugs to market
• Improved clinical trial success rates
• Better drug efficacy prediction
• Better personalization of treatments
• Better regulatory compliance through meeting safety standards

Real-world applications of predictive analytics in pharma

Here is how famous pharmaceutical companies leverage the benefits of advanced analytics in pharma:

Pfizer: Optimizing COVID-19 vaccine development

During the development of its COVID-19 vaccine, Pfizer used predictive analytics extensively to accelerate the clinical trial process. Pfizer used AI and predictive analytics in pharma to drastically reduce the timeline for bringing the vaccine to market, going from initial development to approval in under a year. Moreover, Pfizer used predictive analytics in pharmaceutical logistics to forecast global demand and ensure efficient distribution. This was especially crucial during the initial rollout of vaccines, where demand far outstripped supply.

As a result, Pfizer's COVID-19 vaccine, developed in collaboration with BioNTech, received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) on December 11, 2020. It began global enrollment in the same year (Source ).

The key use of pharma predictive modeling in Pfizer's case was through acceleration of clinical trials. They optimized the trial's design, accelerated the collection of data, and incorporated synthetic control arms in their studies. This is a masterful example to be followed in future global health crises where every month of development matters.

Novartis: A pioneer of data analytics

Novartis is an example of a company that practices multichannel pharma predictive modeling across all areas: for clinical trials, drug development, and supply chain management, but for personalized treatments as well.

One of Novartis' significant innovations involves combining predictive analytics with real-world evidence (RWE). By analyzing large-scale patient data collected from real-world settings—such as hospitals and electronic health records—Novartis can predict how new treatments will perform.

Novartis collaborates with academia: their machine learning algorithms are based on original research conducted by MIT, and over 50 cross-functional teams are working on them (Source ). The company uses a multi-cloud data analytics platform for its predictive analytics in pharma needs. Notable use cases of the platform include DESIRE, a tool for monitoring clinical trial site risks, and a patient services use case that mines call center feedback to improve marketing strategies.

Novartis is also a leader in digital therapeutics and pharma particularly in personalized oncology treatments for common types of cancer—breast, lung, and prostate. A concrete example of Novartis' use of personalized medicine can be found in their application of Kisqali for HER2-positive breast cancer, where clinical trials demonstrated a 29% improvement in survival rates for patients treated with this targeted therapy compared to standard treatments​ (Source ). Predictive analytics in drug development is a key factor in this success thanks to genomic data analysis and clinical trial improvement through machine learning.

Overall, what makes Novartis a true pioneer is that they prioritize pharma predictive analytics and make it a key strategy integrated into all company processes, demonstrating how predictive analytics for pharmaceutical companies means adjusting the entire vision.

Prospects and challenges of predictive analytics in pharma

Predictive analytics in pharmaceutical manufacturing is a complex process associated with many difficulties. Let's consider some of them in more detail:

• Disrupting the current enterprise-level strategy to fit the predictive analytics for pharmaceutical companies

Digital transformation in pharma is never easy. Pharmaceutical companies must adapt their entire operational strategy to accommodate predictive analytics, which often requires a shift from traditional methods to data-driven decision-making.

Shifting to a data-driven model requires extensive restructuring of internal processes, retraining staff to work with advanced analytics, and updating legacy IT systems. This transition can also face resistance from internal stakeholders accustomed to traditional methods.

• Creating infrastructure for pharma data analytics

Building the technical infrastructure (cloud systems, data pipelines, etc.) necessary to support large-scale predictive analytics is costly and time-consuming.

Building infrastructure for large companies' pharma data analytics can cost millions to hundreds of millions of dollars, depending on the complexity. Basic cloud platforms like AWS or Microsoft Azure can cost $500,000 to $1 million annually, while more advanced solutions with integrated AI and data lakes can reach tens of millions.​

• Making sense of unstructured clinical data scattered between various enterprises

Clinical data is often scattered across different systems and is unstructured, making it difficult for pharmaceutical companies to aggregate and analyze effectively.

The hurdles of unstructured data are known as data silos. Unstructured data often requires extensive cleaning to remove irrelevant information and standardize entries, which is resource-intensive and adds up to a cost.

• Complying with data privacy legislation

Pharma companies must navigate complex data privacy regulations (e.g., HIPAA, GDPR), ensuring compliance while maximizing the use of patient data for analytics. On their part, regulations have yet to catch up with the complexity of predictive analytics in the pharmaceutical industry.

The FDA has acknowledged the current need for more specific expertise and regulatory guidance in areas involving AI-driven software products. As a result, the agency advises companies developing such software—especially for more serious, high-stakes applications—to seek external validation.

• Making sense of complex implementation processes

Integrating predictive analytics for pharma supply chain optimization into existing systems involves highly complex processes, including selecting the right technologies and aligning them with business goals.

You need to pick the right AI tools and cloud solutions that align with current systems and make sense for your data types. You also have to account for future scalability and make sure that everything aligns with regulatory requirements.

• Going through the regulatory process

The regulatory approval process for predictive models in drug development can be quite time-consuming due to the need for thorough validation. Regulatory bodies such as the FDA and EMA require companies to prove that these models are accurate and safe, just as they would for any new drug or treatment.

Many predictive analytics in biotech are still new, and it becomes a challenge to select models trustworthy enough to fit the regulations. This can take months or even years, depending on the complexity of the predictive model and the data it uses.

Future prospects

Despite all the challenges, beyond what we have already discussed, predictive analytics in biotech have new prospects that are likely to come to full fruition with further development of technology:

• At the stage of defining an asset strategy, AI and real-world data (RWD) can help companies figure out which new uses (or indications) for their drugs, called novel assets, might be the most promising to develop.
• AI and predictive analytics in pharma with RWD can identify superprogressors among the trial participants that are likely to develop the disease faster and make the trial faster based on this info.
• AI and real-world data (RWD) help pharmaceutical companies figure out the best way to use their drugs. Specifically, AI can identify the right combination of drugs for certain diseases or for specific types of patients. This can prompt the use of drugs earlier in trials for some patients or focus on giving patients the drugs they respond to the best.
• In clinical trials, researchers are trying to figure out if a treatment works by tracking specific endpoints (outcomes they are measuring, like how well a drug improves a condition). AI can help by analyzing data to find alternative endpoints—things that can be measured more easily or more frequently. For example, instead of waiting for a rare event (like a specific symptom), the company might use regular blood tests that give quicker feedback on how the patient is responding.

Final thoughts

Predictive analytics drives faster drug development, optimizes clinical trials, and enables more personalized treatments. By calculating sample sizes and even serving as virtual comparators in some trials, predictive tools can streamline processes, cut costs, and reduce time to market.

However, ensuring data integrity and using transparent methods is critical to gaining widespread adoption. Regulatory bodies are working to catch up, though highly regulated frameworks may risk slowing innovation. Despite these challenges, predictive analytics has vast potential to reshape pharma, improve patient outcomes, and make the industry more resilient to future health challenges.

IT expertise is a key to implementing predictive analytics for pharmaceutical companies. At Binariks, we can help your healthcare company:

• Break down data silos and integrate the data
• Build data infrastructure and assist with cloud migration
• Develop machine learning (ML) models and algorithms
• Build automation tools
• Provide compliance expertise

We don't just offer services—we drive transformation. Our proven expertise in predictive analytics helps pharmaceutical companies accelerate drug discovery, optimize operations, and bring life-changing treatments to market faster.

With our tailored, compliant, and cost-effective approach, you can stay ahead of the curve, enhance patient outcomes, and future-proof your pharma business. Let's reshape the future of healthcare, together.